BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Argenta Discovery Ltd. Expands Collaboration with Genentech (RHHBY) to Include BioFocus DPI


9/10/2010 11:39:21 AM

Harlow and Saffron Walden, UK; 10 September 2010 - Argenta, a service division of Galapagos NV (Euronext: GLPG), announced today it has signed a contract extension with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos' other service division, BioFocus.

Argenta's collaboration with Genentech dates back to 2005. The current agreement covers a number of drug discovery programs that utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech. Under the amendment announced today, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

"We are delighted that Genentech has expanded its small-molecule drug discovery outsourcing into BioFocus, and we regard it as testament to the complementary expertise and technological capabilities that Argenta and BioFocus possess," said Chris Newton, Senior Vice President, Galapagos Services.

About Argenta

Argenta's contract research, which includes expertise in medicinal chemistry, computer-aided drug discovery, in vitro biology, analytics, in vivo pharmacokinetics, pharmacology and world-leading respiratory models, has a strong reputation for scientific excellence. Argenta was acquired by Galapagos in February 2010 and employs over 140 people in the UK with its main operations in Harlow. More info at: www.argentadiscovery.com

About BioFocus

BioFocus aims to expand its partners' drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees in four countries worldwide. More info at: www.biofocus.com

CONTACT

Chris Newton, Senior Vice President, Galapagos Services Tel: +44 1799 533535 bd@glpg.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->